期刊文献+

瑞舒伐他汀治疗慢性肾脏病晚期颈动脉粥样斑块的临床研究 被引量:5

Clinical research of treatment to carotid atherosclerosis with rosuvastatin in stage 4~5 chronic kidney disease
下载PDF
导出
摘要 目的研究瑞舒伐他汀钙对慢性肾病晚期患者颈动脉粥样斑块的疗效。方法选取彩超证实存在颈动脉粥样斑块的慢性肾脏病4~5期患者90例,随机分为三组:A组给予瑞舒伐他汀钙5 mg.d-1,B组给予瑞舒伐他汀钙10 mg.d-1,C组给予阿托伐他汀钙10 mg.d-1,三组年龄和性别相匹配。比较治疗前及治疗12个月后总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白-胆固醇(LDL-C)、高密度脂蛋白-胆固醇(HDL-C)、超敏C反应蛋白(hs-CRP)、肝功能(ALT)、肌酸激酶(CK)水平以及颈动脉内膜中层厚度、粥样斑块数目、大小。结果三组治疗前血脂、hs-CRP水平及颈动脉粥样斑块情况无显著性差异(P>0.05)。三组患者治疗前后比较,治疗后TC、TG、LDL-C、hs-CRP水平均明显下降(P<0.01),HDL-C水平明显升高(P<0.01),其中B组患者血脂及hs-CRP的变化水平较A、C组明显(P<0.01);颈动脉中层厚度治疗后低于治疗前,但仅B组有统计学意义(P<0.05),治疗前后斑块数目无明显改变,B组斑块治疗后较治疗前缩小,A、C组无明显变化。结论常规剂量的瑞舒伐他汀钙可通过调脂、抑制炎症反应等可能机制逆转慢性肾脏病晚期患者颈动脉粥样斑块,并具有良好的安全性。 Objective To investigate the effects of rosuvastatin on carotid atherosclerosis plaques in patients with stage 4/5 chronic kidney disease.Methods A total of 90 stage 4~5 chronic kidney disease patients with carotid atherosclerosis plaques were randomized to rosuvastatin 5 mg·d-1(group A,n=30),rosuvastatin 10 mg·d-1(group B,n=30) and atorvastatin 10 mg·d-1(group C,n=30) for twelve months.The three groups matched for age and gender.The blood lipids including total cholesterol,triglyceride,low density lipoprotein cholesterol and high density lipoprotein cholesterol,highly sensitive C-reactive protein,hepatic function(ALT),creatine kinase(CK),the intima-media thickness(IMT) of carotid arteries,plaque morphology were evaluated before and after treatment.Results The blood lipids levels,the hs-CRP,and the carotid atherosclerosis plaques of three groups before treatment had no significant differences(P0.05).The TC,TG,LDL-C,hs-CRP levels of three groups after treatment for 12 months were significantly decreased compared with before treatment(P0.01),while the HDL-C was increased(P0.01).The change of B group was more apparent than A and C group(P0.01).The IMT after treatment was thinner than before treatment,and there was no significant difference except that in B group(P0.05).After treatment,the count of plaques was not statistically significant among three groups,while the size was significantly decreased in B group.Conclusion Rosuvastatin(10 mg·d-1) can reverse the carotid atherosclerosis plaques in patients with stage 4~5 chronic kidney disease safely.
出处 《安徽医药》 CAS 2012年第3期365-367,共3页 Anhui Medical and Pharmaceutical Journal
基金 江苏省卫生厅面上科研课题(NoH200833)
关键词 瑞舒伐他汀 慢性肾脏病 颈动脉粥样斑块 rosuvastatin chronic kidney disease carotid atherosclerosis
  • 相关文献

参考文献3

二级参考文献28

  • 1吴桥.辛伐他汀治疗不稳定心绞痛40例疗效观察[J].安徽医药,2007,11(1):21-22. 被引量:16
  • 2Rauch U,Osende JI,Chesebro JH.Statins and cardiovascular diseases:the mutiple effects lipid-lowing therapy by statins[J].Atherosclerosis,2000,153(1):181-9.
  • 3Frolkis JP,Pearce GL,Nambi V.Statins do not meet expectatings for lowering low-density lipoprotein cholesterol levels when used in clinical practice[J].AM J Med,2002,113(8):625-9.
  • 4Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504.
  • 5LaRosa JC, Grundy SM, Waters DD, et al; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-1435.
  • 6Pedersen TR, Faergeman O, Kastelein J J, et al; Incremental Decrease in End Points Through Aggressive Lipid Lowedng (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study:a randomized controlled trial. JAMA. 2005;294:2437-2445.
  • 7Grundy SM, Cleeman JI, Merz CN, et al; Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel Ⅲ Guidelines. J Am Coll Cardiol. 2004;44:720-732.
  • 8Blankenhom DH, Azen SP, Kramsch DM, et al;MARS Research Group. Coronary angiographic changes with Iovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med.1993;119:969-976.
  • 9Waters D, Higginson L, Gladstone P, et al. Effects of monotherapy with HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed be serial quantitaUve arteriography: the Canadian Coronary Atherosclerosis Intervention Trial(CCAIT). Circulation. 1994;89:959-968.
  • 10Jukema JW, Bruschke AV, van Boven A J, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation. 1995;91:2528-2540.

共引文献477

同被引文献66

  • 1成威,周胜华,罗顶世,张铭,李旭平.阿托伐他汀对高血压肾病蛋白尿和炎症的治疗作用(英文)[J].中国现代医学杂志,2006,16(2):171-175. 被引量:17
  • 2陈汝筑,黄守坚,主编.治疗药理学[M].北京:人民卫生出版社,2003.173-176.
  • 3侯仁荣.阿托伐他汀对高血压肾病患者肾功能的影响[J].中国中医咨询,2010,2(8):2-6.
  • 4Fridman O,Porcile R,Morales AV,et al.Association of Methyle-netetrahydrofolate reductase gene 677 C > Tpolymorphism with hy-pertension in older women in a population of Buenos Aires City[J].Clin Exp Hypertens,2013,35(3):159-166.
  • 5Miao D,Huang T,Ye P,et al.Homocysteine,not high-sensitivityC-reactive protein,associates with the intima-media thickness ofcarotid artery and arterial stiffness[J].African Journal of Pharma-cy and Pharmacology,2013,7(9):503-511.
  • 6杨凡,王瑞英,李涛涛,等.高敏c反应蛋白,同型半胱氨酸与高血压颈动脉粥样硬化的相关性研究[J].中国心血管病研2012,10(2):93-96.
  • 7Saha A,Sinha PK,Paul R,et al.Study of carotid intima mediathickness and its correlation with novel risk factors in ischemicstroke[J].Neurol Asia,2011,16:25-31.
  • 8Fitzpatrick AM,Jones DP,Brown LA.Glutathione redox control ofasthma:from molecular mechanisms to therapeutic opportunities[J].Antioxid Redox Signal,2012,17(2):375-408.
  • 9Polak JF,Meisner A,Pencina MJ,et al.Variations in common ca-rotid artery intima-media thickness during the cardiac cycle.?impli-cations for cardiovascular risk assessment[J].J Am Soc Echocar-diogr,2012,25(9):1023-1028.
  • 10Verma :S, Buchanan MR, Anderson TJ. Endothelial function testing as a blomarker of vascular disease [ J ]. Circulation, 2003, 108 (17) :2,054 - 2059.

引证文献5

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部